London
· Delayed Price · Currency is GBP · Price in USD Centessa Pharmaceuticals Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 76 |
| CEO | Saurabh Saha |
Contact Details
Address: 1 Ashley Road Altrincham, WA14 2DT United Kingdom | |
| Website | centessa.com |
Stock Details
| Ticker Symbol | 0ACX |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Saurabh Saha | Chief Executive Officer |
| John Crowley | Chief Financial Officer |
| Kristen Sheppard | Head of Investor Relations |